

### **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

#### **Listing of Claims**

1. **(Currently Amended)** A method for eliminating a target cell or antigen from the circulatory system of a subject comprising, administering to the subject a complex comprising monomeric IgA or a portion thereof that binds to Fc $\alpha$ RI, linked to an agent ~~a second portion~~ which specifically binds the target cell or antigen, wherein monomeric IgA and the agent are linked by chemical conjugation or recombinant genetic fusion.

2-5. **(Canceled)**

6. **(Currently Amended)** The method of claim 1, wherein the agent ~~second portion~~ of the complex comprises an antibody or an antibody fragment thereof ~~which specifically binds the target cell or antigen.~~

7. **(Original)** The method of claim 1, wherein the target cell is a cancer cell.

8. **(Original)** The method of claim 1, wherein the target antigen is selected from the group consisting of a bacteria, a virus, and a fungus.

9. **(Original)** The method of claim 1, further comprising the step of administering to the subject a cytokine which increases expression of Fc $\alpha$ RI on Kupffer cells.

10. **(Original)** The method of claim 9, wherein the cytokine is selected from the group consisting of GM-CSF, IL-6, IL-1 $\beta$ , IL-8, and TNF- $\alpha$ .

11. **(Original)** The method of claim 1, wherein the complex is administered by injection.

12. **(Original)** The method of claim 11, wherein the complex is administered intravenously.

13. - 24. **(Canceled)**

25. **(New)** A method for eliminating a target cell or antigen from the circulatory system of a subject comprising, administering to the subject a complex comprising monomeric IgA, linked to an agent which specifically binds the target cell or antigen.

26. **(New)** A method for eliminating a target cell or antigen from the circulatory system of a subject comprising administering to the subject a complex comprising monomeric IgA or a portion thereof that binds to Fc $\alpha$ RI, linked to a non-Fc $\alpha$ RI binding agent which specifically binds the target cell or antigen.

27. **(New)** The method of claim 26, wherein the agent comprises an antibody or an antibody fragment thereof.

28. **(New)** The method of claim 26, wherein the target cell is a cancer cell.

29. **(New)** The method of claim 26, wherein the target antigen is selected from the group consisting of a bacteria, a virus, and a fungus.

30. **(New)** The method of claim 26, further comprising the step of administering to the subject a cytokine which increases expression of Fc $\alpha$ RI on Kupffer cells.

31. **(New)** The method of claim 30, wherein the cytokine is selected from the group consisting of GM-CSF, IL-6, IL-1 $\beta$ , IL-8, and TNF- $\alpha$ .

32. **(New)** The method of claim 26, wherein the complex is administered by injection.

33. (New) The method of claim 32, wherein the complex is administered intravenously.